Background Combining immunosuppressors has been proposed as a strategy to enhance
treatment efficacy in Inflammatory Bowel Disease (IBD). Aim To summarize current evidence …

Metabonomics in inflammatory bowel disease (IBD) characterizes the effector molecules of
biological systems and thus aims to describe the molecular phenotype, generate insight into …

Abstract Background and Aims Dual targeted therapy [DTT] has been proposed as a novel
therapeutic strategy for the management of complicated patients with inflammatory bowel …

Ulcerative colitis (UC) is a chronic and relapsing inflammatory bowel disorder in the colon
and rectum leading to low life‐quality and high societal costs. Ursolic acid (UA) is a natural …

Background: The incidence of Crohn's disease (CD) is increasing worldwide, and it has
currently become a serious public health issue in society. The treatment of CD continues …

Abstract Introduction Evidence suggests that Crohn's disease (CD) pathophysiology goes
beyond the gastrointestinal tract and is also strongly associated with the brain. In particular …

Ulcerative colitis (UC) is a part of incurable chronic inflammatory disease that has gained
importance over the past few decades. A lot of research has been done to find effective …

With the advent of biologic and small molecule therapies, there has been a substantial
change in the treatment of inflammatory bowel disease. These advances have had a great …

Background & Aims Ulcerative colitis (UC) is increasingly recognized as a progressive
disease and patients with long-standing disease can develop colorectal stricture. Few data …

Background Infliximab (IFX) has revolutionised the treatment for Crohn's disease (CD)
recently, while a part of patients show no response to it at the end of the induction period …